Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) released its quarterly earnings data on Tuesday, November, 5th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The company earned $743.70 million during the quarter, compared to analysts' expectations of $770.56 million. Mallinckrodt had a negative net margin of 111.44% and a positive return on equity of 24.36%. The firm's quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.10 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What price target have analysts set for MNK?
14 equities research analysts have issued 1-year price targets for Mallinckrodt's shares. Their forecasts range from $2.00 to $22.00. On average, they expect Mallinckrodt's stock price to reach $8.64 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
Has Mallinckrodt been receiving favorable news coverage?
News coverage about MNK stock has been trending extremely negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mallinckrodt earned a daily sentiment score of -4.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Mallinckrodt.
Are investors shorting Mallinckrodt?
Mallinckrodt saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 46,160,000 shares, a decline of 9.4% from the November 28th total of 50,930,000 shares. Based on an average trading volume of 7,250,000 shares, the days-to-cover ratio is currently 6.4 days. Approximately 55.7% of the shares of the stock are sold short. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Arvinas (ARVN), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), Innoviva (INVA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV) and TG Therapeutics (TGTX).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Strs Ohio (0.20%), Eqis Capital Management Inc. (0.15%), Clear Creek Financial Management LLC (0.03%), Beirne Wealth Consulting Services LLC (0.03%) and Commerzbank Aktiengesellschaft FI (0.02%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.
Which major investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Strs Ohio, Eqis Capital Management Inc. and Clear Creek Financial Management LLC. View Insider Buying and Selling for Mallinckrodt.
Which major investors are buying Mallinckrodt stock?
MNK stock was acquired by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $5.17.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $434.75 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
